NAFLD and cardiovascular disease

Elisabete Martins, MD, PhD, Ana Oliveira, MD

Abstract
Nonalcoholic fatty liver disease (NAFLD) is an important cause of chronic hepatic disease and liver transplant in Western societies. The increasing prevalence is related to dietary changes and sedentarism and follows the increasing frequency of obesity and type 2 diabetes mellitus.

Growing evidence of association of NAFLD with cardiovascular diseases (CVD), independent of cardiovascular risk factors, has prompted the clarification of whether the liver is mainly a key-effector or a target-organ of the metabolic disarrangements in the metabolic syndrome. The therapeutic strategies able to alter liver disease progression and, through this, reduce the cardiovascular risk have also been tested in the last 2 decades.

This review focuses on the possible interactions between hepatic disease, metabolic syndrome, and CVD, and on their implications for clinical practice.

Abbreviations: ANGPTL-8 = Angiopoietin-like protein 8, CVD = Cardiovascular diseases, DPP-4 = Dipeptidyl peptidase-4, FGFR-21 = Fibroblast growth factor 21, GLP-1 = Glucagon-like peptide 1, HDL = High-density lipoprotein, HIF-1α = Hypoxia-inducible factor 1-alpha, 1H-MRS = Proton magnetic resonance spectroscopy, IL = Interleukin, IMT = Intima-media thickness, LEAN = Lipariglutide Efficacy and Action in Non-alcoholic steatohepatitis, LECT2 = Leukocyte cell derived chemotaxin 2, MetS = Metabolic syndrome, NAFLD = Nonalcoholic fatty liver disease, NASH = Nonalcoholic steatohepatitis, PNPLA3 = Patatin-like phospholipase domain containing-3, PPAR = Peroxisome proliferator-activated receptor, PUFA = Polyunsaturated fatty acids, RCT = Randomized controlled trials, SEPP1 = Salenoprotein P, SGLT2 = Sodium–Glucose Co-Transporter 2, SHBG = Sex hormone-binding globulin, T2DM = Type 2 diabetes mellitus, TGF = Transforming growth factor, TM6SF2 = Transmembrane 6 superfamily member 2, TNF = Tumor necrosis factor, VLDL = Very low density lipoproteins.

Keywords: cardiovascular, hepatic steatosis, NAFLD, nonalcoholic fatty liver disease

Hepatic steatosis: Definitions, epidemiology, and diagnosis
Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of chronic liver disease in Western societies. NAFLD mimics the hepatic abnormalities caused by alcohol consumption in patients with a reduced (<30 g in men and 20 g in women) to null daily consumption of alcohol. It is a clinicopathological entity with a wide histological spectrum, starting at hepatic steatosis, defined as fat accumulation in at least 5% of hepatocytes. The natural history of NAFLD, though not established, can be considered in 4 stages: (1) ‘Simple’ steatosis; (2) nonalcoholic steatohepatitis (NASH)—steatosis accompanied by inflammatory changes and “ballooning” (degeneration) of hepatocytes, eventually leading to necrosis; (3) cirrhosis (fibrosis and nodular changes [steatosis may disappear over time]); and (4) hepatocarcinoma (hepatocellular carcinoma, can occur in the absence of cirrhosis).

Risk factors for NAFLD progression (fibrosis) were age >45 to 50, the presence of type 2 diabetes mellitus (T2DM), the degree of insulin resistance, body mass index >28 to 30 kg/m², hypertension, and genetic polymorphisms. The risk of progression associates with the risk of cirrhosis and hepatocarcinoma.

NAFLD frequency has progressively augmented, even in pediatric ages, due to diet changes, sedentary lifestyle, and the increasing prevalence of obesity and T2DM. Its true incidence and prevalence are unknown; estimates of prevalence range widely from 11% to 46%.[1,2] In selected populations, proton magnetic resonance spectroscopy (1H-MRS) revealed hepatic steatosis in 33.6% of 2349 adults. In diabetics, NAFLD may affect up to 70% of the patients.[11,12] NASH affects 3% to 5% of the population.[13] Various NAFLD/NASH cirrhosis is expected to be the major underlying cause for liver transplantation in Western countries by 2020.[14] In the presence of NASH or cirrhosis, the risk of hepatocarcinoma is 7% to 15%.

Commonly used criteria for the clinical diagnosis of NAFLD are the presence of steatosis—demonstrated by imaging or histology—and the absence of excessive alcohol consumption or other causes of steatosis—viruses, drugs, or autoimmunity.

Liver biopsy remains the gold standard for the diagnosis of NAFLD, but results from new imaging methods, such as 1H-MRS, magnetic resonance imaging, or computed tomography, correlate well with histologically detected steatosis. Abdominal ultrasound is still the first-line imaging method in clinical practice, due to its low cost and good accessibility. However, ultrasonography is believed to be of limited sensitivity (60–90%) when less than a third of hepatocytes are steatotic. Liver biochemistry correlates poorly with the presence of NAFLD.
although serum transaminases and γ-glutamyltransferase levels may be elevated.24

**NAFLD and CVD**

Patients with NAFLD have a higher prevalence of clinical cardiovascular diseases (CVD) than control individuals without steatosis. Moreover, CVD are the leading cause of death in NAFLD.25-31

NAFLD is a risk factor for diabetes25 in obese and nonoverweight individuals.33-35 Also, compared to patients who do not have NAFLD, patients with T2DM and NAFLD often have poorer glycemic control, more microvascular complications,36 and an increased risk of all-cause mortality.37

NAFLD and the metabolic syndrome (MetS) components overlap significantly and the main concurrence between the 2 is insulin resistance. Up to 90% of the patients with NAFLD present at least one of the features of MetS—elevated triglycerides, reduced high-density lipoprotein (HDL), and elevated fasting-glucose levels, elevated waist circumference, and elevated blood pressure. One-third meets the MetS diagnosis criteria.38,39

Although the causal association between NAFLD and CVD is controversial,26,29,32,42 the evidence of an independent contribution of hepatic steatosis to clinical coronary heart disease and increased risk of fatal and nonfatal cardiovascular events (in both diabetic and nonobese patients) was provided by more than 20 studies, including meta-analyses.25,29,32,42-46 In those studies, diagnosis of the hepatic disease was made using different methodologies but mostly with ultrasonography.

NAFLD is also associated with subclinical atherosclerosis independently of conventional cardiovascular risk factors.47 A meta-analysis involving 3497 subjects confirmed the association of NAFLD with carotid intima-media thickness (IMT) and with an increased prevalence of carotid plaques.48 In the coronary territory, NAFLD was related to increased artery calcification scores49-52 (Table 1), increased severity of coronary stenosis,53 and abnormal coronary flow reserve.54-56

More uncertainties exist about the relation between the severity of hepatic disease and CVD risk.30,31 The presence of liver fibrosis was associated with cardiovascular organ damage (IMT and left ventricular hypertrophy)56 and increased mortality (hazard ratios of 3.4657 and 4.3658 for cardiovascular death) in patients with higher fibrosis scores.

Compared to those with simple steatosis, patients with NAFLD have more metabolic abnormalities,9,59 and an increasing risk of carotid disease60 and CVD mortality.30,31,61 By contrast, a recent meta-analysis found no significant difference, in terms of cardiovascular risk, between the presence of simple steatosis and NASH.59 Further studies in patients with biopsy-confirmed NAFLD are needed to clarify this issue.

Other NAFLD-related cardiac abnormalities that can explain higher cardiovascular risk include: changes of left ventricular structure and diastolic dysfunction,62-66 myocardial steatosis,67 aortic valve sclerosis,68,69 heart failure,70,71 atrial fibrillation,72,73 cardiac autonomic dysfunction,74 and prolonged heart rate-corrected QT interval.75 The pathophysiology of these associations is diverse and incompletely understood.

**Table 1**

Recent studies (2015–2017) that evaluated the association between nonalcoholic fatty liver disease and coronary artery calcification

| Year of publication; ref. | Total/NAFLD, n | Method used for NAFLD diagnosis | Main results |
|--------------------------|----------------|--------------------------------|-------------|
| 2015                     |                | CT                             | NAFLD is associated with advanced high-risk coronary plaque; OR: 2.13 (95% CI: 1.18–3.85) |
| Puchner et al (Radiology, 2015;274:693–701) | 445/182 | CT                             | NAFLD is associated with significant CAD in type 2 diabetic patients |
| Millman et al (J Diabetes, 2015;7:279–86) | 273/59 | CT                             | NAFLD was independently associated with CACS only in diabetes patients with higher HbA1c |
| Kawak et al (Diabetol Metab Syndr. 2015;7:28) | 213/86 | US                             | NAFLD was associated with increased inflammation and CAC; OR: 1.37 (1.11–1.68) |
| Al Rifai et al (Atherosclerosis. 2015;239:629–33) | 3976/670 | CT                             | NAFLD was an independent predictor of high-risk plaques; OR: 4.60 (95% CI: 1.94–9.07, P<.001) |
| Ouwae et al (PLoS ONE. 2015;10:e0131138) | 414/64 | US                             | The combination of obesity, and fatty liver was independently associated with increase in CACS over time; HR: 2.46 (95% CI: 1.50–4.03) |
| Sung et al (Clin Cardiol. 2016;39:321–8) | 2175/1142 | US                             | In adults with age 67.6±7.0 years, there was no clear association between NAFLD and CACS |
| Jacobs et al (J Clin Gastroenterol. 2016;46:1337–44) | 250/71 | CT                             | The progression of arteriosclerosis and that of liver fibrosis may be associated in NAFLD patients |
| Ishiba et al (Hepatol. 2016;46:1107–17) | 366/94 | CT                             | NAFLD was associated with the development of CAC. Progression rates comparing participants with NAFLD with those without NAFLD was 1.04 (1.02–1.05, P<.001) |
| 2017                     |                | CT                             | Increased risk of coronary artery calcification progression; OR: 2.37 (95% CI: 1.34–4.16) |
| Sinn et al (Gut, 2017;66:323–9) | 4731/2088 | US                             | The concomitant presence of NAFLD and systemic inflammation as assessed by hs-CRP increases the risk of CAC development over 4 years |
| Kang et al (PLoS ONE. 2017;12:e0175762) | 1591/571 | US                             | A low prevalence of NAFLD was found in the T1D cohort that was associated globally with a low proportion of abnormal CVD imaging markers |
| Kim et al (PLoS ONE. 2017;12:e0180118) | 1575/734 | US                             |                        |
| Serra-Planas et al (J Diabetes. 2017;9:1065–72) | 100/12 | US                             |                        |

CAC = coronary artery calcification, CACS = coronary artery calcification score, CAD = coronary artery disease, CI = confidence interval, CT = computed tomography, CVD = cardiovascular disease, HR = hazard ratio, hs-CRP = high sensitivity C-reactive protein, IR = insulin resistance, NAFLD = nonalcoholic fatty liver disease, OR = odds ratio, T1D = type 1 diabetes, US = ultrasonography.
Pathophysiological links

Regarding NAFLD and CVD, it is crucial to determine whether hepatic steatosis is an independent cardiovascular risk factor or a surrogate manifestation of a systemic atherogenic metabolic milieu—in particular, of insulin resistance. As a fundamental regulator of lipid and glucose metabolism, the liver can be the trigger and/or target of a metabolic syndrome.

The mechanisms of NAFLD development are largely unknown, probably multifactorial and resulting from complex interactions between environmental and genetic factors. The contribution of parallel factors, acting synergistically in genetically predisposed individuals, is the basis for the “multiple-hit” hypothesis for NAFLD development and progression

Environmental factors include hypercaloric diets (particularly those rich in saturated fats, refined carbohydrates, and high fructose-sweeteners) and sedentarism. Both are associated with obesity (abdominal), metabolic syndrome, and NAFLD.

The hallmark of NAFLD is triglyceride accumulation in the cytoplasm of hepatocytes due to an imbalance between lipid acquisition (ie, fatty acid uptake and de novo lipogenesis) and lipid removal (ie, mitochondrial fatty acid oxidation and export as a component of very low density lipoproteins [VLDL] particles). The excessive caloric intake results in a spillover of nonesterified fatty acids from adipose visceral tissue to ectopic fat storage (namely the liver), due to insufficient oxidation and VLDL secretion. Peripheral lipolysis in peripheral adipose tissue, aggravated by insulin resistance, is the source of most hepatic lipids but de novo lipogenesis also plays a substantial role in the pathogenesis of NAFLD.

There is an important cross-talk between the liver and the expanded, ectopic and dysfunctional (inflamed) adipose tissue. This affects the metabolism of fatty acids, promoting the deposition of triglycerides in organs such as the liver itself. The adipose tissue significantly contributes to the systemic metabolic state, due to an unbalance between inflammatory and anti-inflammatory/anti-fibrotic adipocytokines. High tumor necrosis factor (TNF)-α and low adiponectin levels are associated with NAFLD, independently of insulin resistance.

In turn, the accumulation of intrahepatic fat changes the insulin signal at the hepatic level, promoting gluconeogenesis, which then promotes hyperglycemia and increases the risk of T2DM.

Liver damage caused by fat accumulation is due to several mechanisms including lipotoxicity, increased oxidative stress, endothelial dysfunction, apoptosis, and inflammation. Hepatic lipid accumulation leads to subacute hepatic inflammation via nuclear factor κB activation by releasing proinflammatory cytokines such as interleukin-6 (IL)-6, IL-1β, and TNF-α.

Pathologic liver angiogenesis has also been described in NAFLD although less prominent than in conditions of bridging or postnecrotic fibrosis (eg, in chronic viral infection). A connection between pathologic angiogenesis and fibrogenesis is suggested by experimental models of antiangiogenic therapy that are highly effective in reducing fibrogenic progression.

Leptin, an adipocytokine elevated in NAFLD patients, exerts profibrogenic effects during the progression from NAFLD to NASH and also operates as a proangiogenic mediator through the recruitment and stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) and the nuclear translocation of HIF.

The liver is recognized as an endocrine organ that secretes hepatokines. These regulate systemic metabolism and energy homeostasis, and may contribute to the pathogenesis not only of NAFLD but also of metabolic syndrome, T2DM and CVD.

Some of the most recently recognized hepatokines involved in NAFLD pathogenesis are Fetuin-A, fibroblast growth factor 21 (FGF-21), selenoprotein P (SEPP1), sex hormone-binding globulin (SHBG), angiopoietin-related growth factor, and...
leukocyte cell-derived chemokine 2 (LECT2). Fetuin-A might constitute a link between obesity, insulin resistance, and NAFLD—it binds the insulin receptor in tissues, inhibiting insulin signaling and therefore inducing insulin resistance.\textsuperscript{84,85} Circulating FGF-21, also considered a metabolic regulator, significantly correlates with the hepatic fat content and could be regarded as a noninvasive biomarker useful in differentiating simple fatty liver from NASH.\textsuperscript{86} Serum LECT2 levels are also significantly higher in patients with obesity and NAFLD.\textsuperscript{87} On the contrary, serum concentrations of SHBG decreased with an increase of intrahepatic fat content.\textsuperscript{88}

In patients with T2DM and with NAFLD alike, SEPP1, a selenium-carrier protein, correlated with cardiovascular risk factors (eg, subclinical parameters of inflammation and arterial stiffness).\textsuperscript{89} More recently, angiopeptin-like protein 8 (ANGPTL-8) was pointed as a predictor of significant NAFLD, independent of obesity and insulin resistance, and could also be a potential therapy target of NAFLD.\textsuperscript{90}

Exploring the mechanisms of these and other hepatokines can determine their usefulness as biomarkers of NAFLD, of disease progression or of CVD risk or as primordial metabolic therapeutic targets. Further experimental and clinical studies are necessary to confirm these hypotheses.

Genetic factors also account for a significant percentage of hepatic fat variability.\textsuperscript{91} Single nucleotide polymorphisms in genes involved in lipid metabolism (Lipin 1, patatin-like phospholipase domain containing-3 [PNPLA3]), oxidative stress (superoxide dismutase 2), insulin signaling (insulin receptor substrate-1), and fibrinogenesis (Kruppel-like factor 6) are associated with a risk for the development and progression of NAFLD.\textsuperscript{92}

Carriers of the genetic variant p.I148M (rs738409 C/G) in PNPLA3 gene have a higher risk of liver damage in the presence of external noxious, raised levels of aspartate aminotransferase and/or alanine aminotransferase,\textsuperscript{93} and more severe NASH with greater levels of fibrosis.\textsuperscript{94,95} PNPLA3 gene is recognized as a modifier in terms of NAFLD disease severity and risk of related hepatocarcinoma,\textsuperscript{96} but is not associated with insulin resistance\textsuperscript{97} and has apparently no significant effect on NAFLD-related CVD risk.\textsuperscript{98,99}

The dissociation between genetic and metabolic-driven NAFLD in terms of CVD risk was also put in evidence in another study, where carriers of the transmembrane 6 superfamily member 2 (TM6SF2) E167K variant were more susceptible to severe NASH with greater hepatic inflammation, fibrosis, ballooning, and hepatic disease severity.\textsuperscript{113} A general objective is to reduce both liver-related complications and CVD. However, restricting calories intake, aiming for a weight loss of at least 5% – 10%.\textsuperscript{114}

Lifestyle changes

Since NAFLD is mainly a manifestation of obesity and metabolic syndrome, lifestyle modification remains the cornerstone of prevention and treatment. Weight loss, diet, and regular exercise have all independent beneficial effects on hepatic disease.

Even modest losses of weight improve steatosis, inflammation, ballooning, and hepatic disease severity.\textsuperscript{113} A general objective is restricting calories intake, aiming for a weight loss of at least 5% to 10%.\textsuperscript{114}

Bariatric surgery, reserved to patients with severe obesity, also improves hepatic steatosis,\textsuperscript{115} but rapid weight reduction should be avoided.\textsuperscript{116,117} Insufficient data are available regarding antiobesity therapies including orlistat, an inhibitor of pancreatic lipase.\textsuperscript{118}

Concerning diet, there are few data on the effect of macronutrients. Adherence to the Mediterranean diet (with increased polyunsaturated fatty acids intake, reduced fat and carbohydrates intake, high fiber diet) has known beneficial effects,\textsuperscript{119,120} even in pediatric patients,\textsuperscript{121} as also the avoidance of fructose-sweeteners.\textsuperscript{122}

The effect of alcohol in patients with NAFLD is still debated. Light-to-moderate alcohol consumption may exert some beneficial effect on the severity of NAFLD.\textsuperscript{123,124}
Regular exercise contributes to increasing insulin sensitivity and abdominal fat reduction. There is an inverse relationship between exercise and NAFLD, independent of weight loss.\(^{125,127}\) The optimal physical activity regimen still remains to be determined. A recent trial showed that 4 months of resistance training and aerobic training were equally effective in patients with T2DM.\(^{128}\)

**Pharmacological treatments**

There are no pharmacological agents approved specifically for NAFLD treatment, so the main concern is patients with NASH, who have the higher risk of disease progression.

Considering known pathophysiologic links involved in NAFLD, different pharmacologic approaches have been tested; however, until now, there is a lack of large randomized controlled trials (RCT) reporting histological outcomes.

As insulin resistance is an essential requirement for the accumulation of hepatocellular fat, most studies have focused on the effects of antidiabetic drugs.

Metformin, used for decades for the treatment of T2DM, improves insulin resistance, but displays marginal effects on transaminases, with no improvement in steatosis or inflammation in NAFLD, in larger controlled clinical trials.\(^{129}\)

By contrast, pioglitazone, a thiazolidinedione which acts as a selective agonist of peroxisome proliferator-activated receptor (PPAR)-\(\gamma\) improving systemic and hepatic insulin sensitivity, is the drug with the highest level of evidence for the treatment of NASH in patients with prediabetes/T2DM, as it improved steatosis and inflammation and may reduce hepatic fibrosis.\(^{130,131}\)

Another PPAR modulator, elafibranor (GFT505), combines PPAR-\(\alpha\) effects, which primarily enhance lipid metabolism, with PPAR-\(\delta\) effects, which target more glucose homeostasis. In GOLDEN trial,\(^{132}\) it was tested in patients with biopsy-proven NASH with a primary histological end-point: NASH resolution without fibrosis worsening. This result was achieved in 23% and 21% of patients treated with 80 and 120 mg/d, respectively, leading to a large multicenter RCT in patients with more severe steatohepatitis.

Incretin mimetics, as glucagon-like peptide 1 (GLP-1) receptor agonists (exenatide and liraglutide), increase insulin sensitivity, lower postprandial glucagon levels, and induce weight loss.\(^{133,134}\) Liraglutide may improve hepatic steatosis,\(^{136}\) and in Liraglutide Efficacy and Action in Non-alcoholic steatohepatitis (LEAN) trial was able to resolve biopsy-proven NASH in 39% of the treated patients. However, it is still uncertain if the treatment benefit was caused by the weight reduction (responders had a mean weight loss of 2.1 kg).\(^{137}\) The drug should be tested further in larger studies with long follow-ups.\(^{138}\)

Dipeptidyl peptidase-4 (DPP-4) inhibitors exert glucose-lowering effects primarily by blocking the enzyme DPP-4 that degrades GLP-1, and so enhances the endogenous level of GLP-1. Sitagliptin and vildagliptin reduce plasma aminotransferases\(^{139,140}\) and could ameliorate hepatic steatosis and inflammation,\(^{141}\) but limited clinical data are still available.

There are also no studies assessing the effect on NAFLD patients liver histology of Sodium–Glucose Co-Transporter 2 (SGLT2) Inhibitors (canagliflozin or dapagliflozin), agents that lower renal glucose absorption.

Beyond antidiabetics, other agents with different mechanisms of action have been tested in NAFLD, with different results.

Omega-3 polyunsaturated fatty acids (\(\omega-3\) PUFA) have long been credited with reducing hepatic steatosis. Potential actions may be the regulation of hepatic gene expression, the improvement of insulin sensitivity, and the reduction of inflammation and of oxidative stress.\(^{142}\) The WELCOME Trial tested the effects of the regular ingestion of 4 g of eicosapentaenoic acid plus docosahexaenoic acid (approved for treatment of hypertriglyceridemia),\(^{143}\) and showed an improvement of NAFLD.\(^{144}\) However, other trials have been overall negative.\(^{145,146}\) It is also possible that particular PUFA may be more beneficial than others.

Considering chronic oxidative stress as a key mechanism in liver damage and NAFLD progression, in PIVENS study vitamin E (\(\alpha\)-tocopherol)—an antioxidant—was administered to non-diabetics, 800 IU/d for 96 weeks, resulting in improved steatosis, inflammation, and hepatocellular ballooning;\(^{147}\) however, further evidence is necessary to support the efficacy of this fat-soluble agent for the treatment of NASH.

Considering the metabolic, anti-inflammatory and antifibrotic effects of vitamin D on hepatocytes\(^{148}\) and that NAFLD subjects are more likely to be vitamin D deficient, its use in NAFLD was tested in a small double-blind, placebo-control study. The obtained negative results in terms of steatosis markers warrant more studies to demonstrate the benefits with this vitamin supplementation.\(^{149}\)

The use of acid obeticholic—a potent activator of the farnesoid X-nuclear receptor that regulates bile acid, glucose, and cholesterol homeostasis—also resulted in the improvement of steatosis, hepatocellular ballooning, and lobular inflammation in the FLINT trial.\(^{150}\) Compared to placebo, the NASH resolution was obtained in 22% of treated patients. One mechanism proposed to explain this benefit is the inhibition of intestinal cholesterol absorption by modulation of the bile acid pool, thus increasing reverse cholesterol transport.\(^{151}\) Long-term safety of this drug needs to be addressed and a phase III study is now ongoing.

Pentoxifylline inhibits a number of proinflammatory cytokines including TNF-\(\alpha\) and may be hepatoprotective and antifibrogenic. In a randomized placebo-controlled trial, pentoxifylline improved histologic features of NASH\(^{152}\) but larger studies are needed especially to corroborate the effects on liver fibrosis.

Statins did not ameliorate the histological parameters in NASH.\(^{153}\) However, the treatment of dyslipidemia and of other features of the metabolic syndrome should be a primary target in patients with NAFLD.\(^{154}\) Statins may be safely prescribed and the risk of hepatotoxicity does not appear to be increased, even with NASH.\(^{154}\) Therapeutic targets are not specific for patients with NAFLD.

In hypertensive patients, inhibitors of the renin–angiotensin system should be the first choice agents, due to their potential antifibrogenic and insulin-sensitizing effects, although no robust data with hepatic histological endpoints are available.\(^{155,156}\)

Several phase II clinical trials are ongoing to evaluate the effect of newer drugs with effects on different pathogenic pathways involved in NASH. These include anti-inflammatory, antifibrotic, antiapoptotic, and new metabolic modulator agents. FGF-19 or FGF-21 analogs, dual antagonist of chemokine receptors 2 and 5 and antilysyloxidase-like-2 monoclonal antibodies are examples of the diversity of drugs that are being tested for the treatment of NASH.\(^ {157}\)

It will be interesting to get data on genotypes and organokines’ profiles when interpreting the effect of different drugs.

Until effective drugs are available to treat NASH cirrhosis, liver transplantation use is expected to increase in the next 1 to 2 decades. It is important to know that the liver recipients are at...
risk for recurrence of NAFLD in the graft. A recent systematic review and meta-analysis compared survival and causes of death after liver transplantation for NASH and other etiologies. One-, three-, and five-year patient survivals were similar in NASH and non-NASH recipients; however, CVD events and sepsis were more frequent as causes of death in NASH recipients.

Conclusion and future developments

The association between hepatic steatosis and CVD expands the spectrum of manifestations of unfavorable proatherogenic metabolic states, allowing the identification of new risk markers and the development of new therapeutic targets.

However, there lacks a clarification of the causal relationship between NAFLD and CVD, as well as of the complex interactions between genetic and environmental factors. The effectiveness of new therapeutic interventions also needs to be verified. Finally, the best cardiovascular risk score for patients with NAFLD needs to be further validated and vice versa, it is crucial to know if NAFLD/NASH should be included in CVD risk score panels.

Acknowledgment

None.

Conflicts of interest

The authors declare no conflicts of interest.

References

[1] Rector RS, Thyzault JP, Wei Y, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol. 2008;14:185–192.

[2] Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011;343:d3897.

[3] Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis. 2012;30(supp 1):61–68.

[4] Pickhardt PJ, Hahn L, Munoz del Rio A, et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol. 2014;202:732–738.

[5] Ratzou V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–384.

[6] Kitamoto T, Kitamoto A, Yoneda M, et al. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAA3M50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2011;132:783–792.

[7] Masarone M, Federico A, Abenavoli L, et al. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9:126–133.

[8] Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28:339–350.

[9] Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.

[10] Szczepaniak LS, Nurengberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–E468.

[11] Williamson RM, Price JF, Glancy S, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2013;36:1139–1144.

[12] Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119.

[13] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.

[14] Silverman JP, Pories WJ, Caro JF. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu. 1989;24:275–302.

[15] Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–1058.

[16] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005–2023.

[17] Thomopoulos KC, Arvanit V, Tsamantas AC, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol. 2006;18:233–237.

[18] Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2013;17:533–546.

[19] Yatsuji S, Hashimoto E, Kaneda H, et al. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol. 2005;40:1130–1138.

[20] Karlas T, Petroff D, Garnov N, et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy, PLoS ONE. 2014;9:e91987.

[21] Schwener NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433–445.

[22] Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011;54:1082–1090.

[23] Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292.

[24] Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2012;56:234–240.

[25] Targher G, Bertolmi L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218.

[26] Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646–650.

[27] Lazo M, Hernaez R, Bonekamp S, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891.

[28] Matteoni CA, Younossi ZM, Gramlich T, et al. Prevalence of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113–121.

[29] Esketd M, Fanren LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865–873.

[30] Suderberg C, Stal P, Amling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595–602.

[31] Lu H, Liu H, Hu F, et al. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol. 2013;2013:1249584.

[32] Musso G, Gambino R, Cavadini R, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649.

[33] Fraser A, Harris R, Sattar N, et al. Alamine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care. 2009;32:741–750.

[34] Fukuda T, Hamaguchi M, Kojima T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int. 2016;36:273–283.
[36] Targher G, Pichiri I, Zoppini G, et al. Increased prevalence of chronic kidney disease in patients with type 1 diabetes and non-alcoholic fatty liver. Diabet Med. 2012;29:220–226.

[37] Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105:1567–1573.

[38] Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487–500.

[39] National Cholesterol Education Program Expert Panel on Detection E. Elevated blood cholesterol in adults (Adult treatment panel III/Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–3421.

[40] Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60:1721–1727.

[41] Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750–755.

[42] Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579–1584.

[43] Haring R, Wallaschofski H, Nauck M, et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology. 2009;50:1403–1411.

[44] Zhou YJ, Li YY, Nie YQ, et al. Natural course of nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010;105:1567–1573.

[45] Fraser A, Harris R, Sattar N, et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women’s Heart and Health Study and Meta-Analyses. Arterioscler Thromb Vasc Biol. 2007;27:2729–2735.

[46] Xu R, Yang HN, Li YQ, et al. Association of coronary artery calcium with bone mineral density in postmenopausal women. Coron Artery Dis. 2016;27:586–591.

[47] Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and associated with vascular disease. J Am Coll Cardiol. 2010;56:225–233.

[48] Sesti G, Sciacqua A, Fiorentino TV, et al. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS ONE. 2014;9:e104941.

[49] Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–1365.

[50] Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2013;61:1547–1554.

[51] Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014;20:8407–8415.

[52] Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care. 2006;29:1325–1330.

[53] Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7:234–238.

[54] Goland S, Shimoni S, Zimniak T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006;40:948–955.

[55] Forbolc H, Yayak T, Duman D, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J. 2010;17:457–463.

[56] Hallworth K, Hollingsworth KG, Thoma G, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58:757–762.

[57] Fallo F, Dalla Pozza A, Sonino N, et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis. 2009;19:646–653.

[58] Mantovan G, Zoppini G, Targher G, et al. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals. J Endocrinol Invest. 2012;35:215–218.

[59] Rijzewijk LJ, Jonker JT, van der Meer RW, et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol. 2010;56:225–233.

[60] Markus MR, Baumeister SE, Stritze J, et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler Thromb Vasc Biol. 2013;33:1690–1695.

[61] Bonapace S, Valbusa F, Bertolini L, et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE. 2014;9:e83871.

[62] Dhingra R, Gona P, Wang TJ, et al. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol. 2010;30:1855–1860.

[63] Wannamethee SG, Whincup PH, Shaper AG, et al. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol. 2012;32:830–835.

[64] Sinner MF, Wang N, Fox CS, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. J Am Cardiol. 2013;111:219–224.

[65] Targher G, Valbusa F, Bonapace S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE. 2013;8:e57183.

[66] Newton JL, Pairman J, Wilton K, et al. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009;19:319–326.

[67] Sinner MF, Wang N, Fox CS, et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. J Am Cardiol. 2013;111:219–224.

[68] Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE. 2013;8:e57183.

[69] Newton JL, Pairman J, Wilton K, et al. Fatigue and autonomic dysfunction in non-alcoholic fatty liver disease. Clin Auton Res. 2009;19:319–326.

[70] Targher G, Valbusa F, Bonapace S, et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014;24:663–669.

[71] Uzunuzlu E, Pinzani M, Tischatsch EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038–1048.

[72] Abdelmalek MF, Suzuki A, Goy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961–1971.

[73] Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:343–441.

[74] Donnelly KL, Smith CI, Schwarzenberg SJ, et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2003;115:1343–1351.

[75] Hui JM, Dodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46–54.

[76] Samuel VT, Lui ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 2004;279:32345–32353.

[77] Bosco C, Novo E, Migliotta A, et al. Angiogenesis and fibrogenesis in chronic liver diseases. Cell Mol Gastroenterol Hepatol. 2015;3:477–488.
[109] Nascimbenti F, Pais R, Bellentani S, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;61:1483–1497.

[107] Trenspeerboom S, Leverage S, Adams LA, et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 2012;32:943–950.

[105] Bell KJ, Hayen A, Irwig L, et al. When to remeasure cardiovascular risk in untreated people at low and intermediate risk: observational study. BMJ. 2013;346:f1895.

[103] Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:2748–2764.

[102] Thoma C, Day CP, Tremell ML. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012;56:255–266.

[100] Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156–2163.

[99] Rahl C, Campos GM. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis. 2012;32:80–91.

[98] Furuya CK Jr, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol. 2007;22:510–514.

[97] Lassailly G, Cairosso R, Boulo D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology. 2015;149:379–388.

[96] Harrison SA, Fecht W, Brunt EM, et al. Olistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology. 2009;49:80–86.

[95] Ryan MC, Iosipoulos C, Thodis T, et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with nonalcoholic fatty liver disease. J Hepatol. 2013;59:138–143.

[94] Kontogianni MD, Tileli N, Margarini A, et al. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. Clin Nutr. 2014;33:678–683.

[93] Della Corte C, Mosca A, Vania A, et al. Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: the results of an Italian study. Nutrition. 2017;39:40–48.

[92] Carvallana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:468–473.

[91] Dunn W, Xu K, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology. 2008;47:1947–1954.

[90] Moriya A, Iwasaki Y, Oshuga S, et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:378–388.

[89] Johnson NA, George J. Fitness versus fatteness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology. 2010;52:370–381.

[88] Hallsworth K, Fattakhova G, Hollingsworth KG, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60:1278–1283.

[87] Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.

[86] Bacchi E, Negri G, Targher G, et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). Hepatology. 2013;58:1287–1295.

[85] Musso G, Cassader M, Rosina F, et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885–904.

[84] Bellfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297–2307.

[83] Cusi K, Orsak B, Bel F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165:305–315.

[82] Ratziu V, Harrison SA, Franque S, et al. Eflibrinoran, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147–1159.
[133] Cuthbertson DJ, Irwin A, Gardner CJ, et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE. 2012;7:e50117.

[134] Gupta NA, Melis J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51:1584–1592.

[135] Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–837.

[136] Kahal H, Abouda G, Rigby AS, et al. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;81:323–328.

[137] Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387:679–690.

[138] Wong VW, Wong GL. A LEAN treatment for non-alcoholic steatohepatitis. Lancet. 2016;387:628–630.

[139] Ohki T, Isogawa A, Iwamoto M, et al. The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone. ScientificWorldJournal. 2012;2012:496453.

[140] Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100:1578–1585.

[141] Kern M, Kloting N, Niessen HG, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS ONE. 2012;7:e38744.

[142] Del Ben M, Polimeni L, Baratta F, et al. Modern approach to the clinical management of non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:8341–8350.

[143] Kris-Etherton PM, Harris WS, Appel LJ, et al. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151–152.

[144] Scorletti E, Bhatia L, McCormick KG, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study. Hepatology. 2014;60:1211–1221.

[145] Sanyal AJ, Abdelmalek MF, Suzuki A, et al. No significant effects of ethyl-icosapentaeonic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147:377.e1–384.e1.

[146] Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol. 2015;49:137–144.

[147] Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675–1685.

[148] Eliades M, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol. 2015;21:1718–1727.

[149] Sharifi N, Amani R, Hajiani E, et al. Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine. 2014;47:70–80.

[152] Nelson A, Torres DM, Morgan AE, et al. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009;43:990–994.

[153] Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376:1916–1922.

[154] Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225.

[155] Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16:39–46.

[156] Italian Association for the Study of the Liver (AISF)AISF position paper on hepatic steatosis. J Clin Endocrinol Metab. 2015;100:1578–1585.

[157] Macauley M, Hollingsworth KG, Smith FE, et al. Effect of vildagliptin on hepatic steatosis. J Clin Endocrinol Metab. 2015;100:1578–1585.

[158] Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis. Lancet. 2010;376:1916–1922.

[159] Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225.

[160] Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007;16:39–46.

[161] Italian Association for the Study of the Liver (AISF)AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. Dig Liver Dis. 2017;49:471–483.

[162] Zistros P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15532–15538.